PEGylated PLGA Nanoformulations For Effective Immunomodulatory Actors In Non–Small Cell Lung Cancer

Abstract

Abstract PEGylated poly(lactic-co-glycolic acid) (PEG-PLGA) nanoparticles have attracted increasing attention as a versatile and biocompatible nanoplatform for non-small cell lung cancer (NSCLC) therapy. Benefiting from prolonged circulation time, controllable drug-release behavior, and flexible surface modification, PEG-PLGA nanocarriers can effectively enhance tumor accumulation while reducing systemic toxicity. Recent advances indicate that PEG-PLGA nanoparticles not only improve the delivery efficiency of chemotherapeutic agents but also enable active tumor targeting through ligand conjugation and contribute to the regulation of the tumor immune microenvironment. In particular, these nanoplatforms have shown promising potential in enhancing antigen presentation, alleviating immunosuppression, and synergizing with immunotherapeutic strategies such as immune checkpoint blockade. Nevertheless, several challenges remain for clinical translation, including large-scale manufacturing, formulation reproducibility, and regulatory considerations. Overall, this review highlights the current progress, remaining challenges, and future perspectives of PEG-PLGA nanoparticles for targeted and immune-based therapies in NSCLC.